Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on Myovant Sciences, Inc.

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

Myovant Sciences Sciences is a US public company that focuses on treatments for women’s health diseases and other endocrine-related disorders. It plans to raise $300 million in a secondary public offering, as reported in the PharmSource Lead Sheet on November 16, 2017.

Corporate Highlights

  • Myovant Sciences was incorporated in Bermuda in February 2016 under the name Roivant Endocrinology Ltd. and changed its name to Myovant Sciences in May 2016.
  • Corporate Headquarters: Brisbane, CA
  • As of March 31, 2017, they had 36 employees
  • Stock Exchange: NYSE
  • Stock Symbol: MYOV

Sourcing Opportunities

  • Myovant Sciences plans to use the proceeds to fund its clinical development programs for relugolix and MVT-602:
    • MVT-602 To complete preclinical studies:
      • For treatment of female infertility
      • Dosage Form: Unknown
      • Nature of API: Unknown
      • Therapeutic Areas: Gynecology/Obstetrics
    • Relugolix To complete Phase III clinical studies:
      • For treatment of uterine fibroids, prostate cancer and endometriosis-associated pain
      • Dosage Form: Tablet
      • Nature of API: Chemical – Normal potency
      • Therapeutic Areas: Gynecology/Obstetrics; Analgesic – Non-narcotic
  • The company contracts with contract research organizations (CROs) to conduct clinical trials.
  • Myovant Sciences does not own or operate manufacturing facilities and relies on third party contract manufacturers for all required raw materials, API and finished product for preclinical studies and clinical trials.
  • Myovant Sciences has no sales, marketing or distribution capabilities or experience.

Business Relationships

  • In April 2016, Myovant Sciences and Takeda enter into a license agreement for the development and commercialization of relugolix and MVT-602. Takeda retains rights in Japan, China, Hong Kong, Indonesia, Korea, Malaysia, Philippines, Singapore, Taiwan, Thailand, and Vietnam. Financial terms were undisclosed.

Pipeline

Product Candidate Indication Dosage Form Status Next Anticipated Step
MVT-602 Female Infertility Unknown Preclinical TBA
Relugolix Uterine Fibroids – Heavy Menstrual Bleeding Tablet Phase III TBA
Relugolix Endometriosis-associated pain Tablet Phase III TBA
Relugolix Advanced Prostate Cancer Tablet Phase III TBA

Finance

(In $ thousands) 2017 2016
Revenue
R&D Expenditures 43,500
General & Administrative Expenditures 12,357 1,657
Total Operating Expenses 55,857 1,657

Contact Information

Myovant Sciences, Inc. Key Officers
2000 Sierra Point Parkway, 9th Floor Lynn Seely, President & CEO
Brisbane, CA, 94005 USA Bryan Selby, SVP, Product Development
Phone: +1-650-238-0250 Juan Camilo Arjona Ferreira, MD, CMO
Web: http://myovant.com/ Teresa Perney, PhD, SVP, Regulatory Affairs & QA

 

Related posts:
Follow the Money to Pharmaceutical Opportunities – Spotlight on Protagonist Therapeutics, Inc.
Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on ARMO BioSciences, Inc.

Follow the Money to Pharmaceutical Opportunities – Spotlight on CymaBay Therapeutics

Scotty is a Research Analyst at PharmSource. He holds a BS degree in Biology from George Mason University and an MPH degree from Eastern Virginia Medical School. He’s experienced in data collection, analysis and management, and has done laboratory analysis and safety program development.

More posts by Scotty Chung-Siu